Medicare Advantage appeal help for Kentucky and Ohio families facing Part C medical denials and Part D drug denials.
A denial letter is not a policy debate. It arrives in the middle of real life.
It lands while a parent is in rehabilitation. It arrives when a scan has already been ordered, a discharge is already being planned, or a prescription has already become part of daily survival. It uses calm, bureaucratic language to deliver something that feels anything but calm: no. Not covered. Not approved. Not medically necessary.
The letter appears final because it is designed to do so.
Often, it is not.
According to KFF, Medicare Advantage insurers made 52.8 million prior authorization determinations in 2024 and denied 4.1 million, or 7.7%, of them. Only 11.5% of those denials were appealed. But when appeals were filed, 80.7% were overturned in whole or in part. That does not prove every denial was wrong. It does show that many denials do not survive closer review.
This article is for people in Kentucky and Ohio trying to understand a denial involving Medicare Advantage (Part C) or Medicare prescription drug coverage (Part D). Because these appeals are governed largely by federal Medicare rules, the same core framework applies whether you live in Kentucky or Ohio. CMS maintains separate appeals and grievances frameworks for Medicare managed care and Medicare prescription drug coverage.
Quick answer: What should you do first after a Medicare Advantage denial?
Read the notice carefully. Figure out whether the denial involves medical care under Part C or a prescription drug under Part D. Calendar the deadline immediately. Gather the records that answer the insurer’s stated reason for denial. And if waiting could seriously jeopardize the patient’s health, ask about an expedited appeal right away. CMS says it updated the Parts C and D guidance in November 2024 to extend the timeframe for submitting an appeal from 60 calendar days to 65 calendar days from the date of the notice, effective January 1, 2025. (CMS)
What is Medicare Advantage?
Medicare Advantage is the private-plan version of Medicare. Medicare.gov explains that a Medicare Advantage Plan (Part C) is a Medicare-approved health plan from a private company that you can choose instead of Original Medicare to cover most of your Part A and Part B benefits, and that it usually also includes Part D drug coverage. Medicare.gov also explains that Medicare Advantage is another way to get your Part A and Part B benefits instead of Original Medicare.
That means Medicare Advantage is not separate from Medicare. It is one way to get Medicare benefits, but through a private insurer that contracts with Medicare and must follow its rules.
What is Medicare Part C?
Part C is the formal name for Medicare Advantage. When this article refers to a Part C denial, it usually means a denial of medical care or treatment under a Medicare Advantage plan. CMS’s managed-care appeals materials use that Part C terminology, describe the plan’s initial coverage decision as an organization determination, and describe the first appeal as a reconsideration.
In real life, Part C disputes often involve inpatient rehabilitation, skilled nursing facility care, home health services, imaging, surgeries, specialist care, or certain physician-administered drugs covered under Part B. Those are examples of the kinds of medical services that fall within the Medicare Advantage managed-care appeals framework.
What is Medicare Part D?
Part D is Medicare’s prescription drug coverage. Medicare.gov says Part D is extra coverage people with Medicare can choose to help lower prescription-drug costs, that Medicare-approved private plans offer this coverage, and that it helps pay for both brand-name and generic drugs.
In practical terms, Part D is the part of Medicare that helps pay for outpatient prescription medications. When a patient is denied a medication, blocked by prior authorization, forced through step therapy, or hit with a quantity limit, the dispute often falls into the Part D system. CMS refers to the first plan-level appeal as a redetermination.
What does Part C cover, and what does Part D cover?
Part C generally covers the hospital and medical benefits a person would otherwise receive under Original Medicare Parts A and B, but through a private Medicare-approved plan. Medicare.gov says Medicare Advantage plans cover Parts A and B and usually include Part D drug coverage.
Part D covers prescription drugs, but every drug plan has its own rules. Medicare.gov explains that drug plans may have rules for when and how they cover drugs, including prior authorization, step therapy, and quantity limits.
What is a formulary?
Formulary means the drug plan’s official list of medications it agrees to cover. If your prescription is not on that list, the plan may deny coverage unless you qualify for an exception or win an appeal.
Medicare.gov explains that a plan’s list of covered drugs is called a formulary, and that each plan has its own formulary.
That one word matters more than many families realize. A drug can be medically important and still be denied because it falls outside the plan’s formulary or because the plan imposes other restrictions, such as prior authorization, step therapy, or quantity limits. Medicare.gov lists those rules explicitly.
Why are Medicare Advantage denials getting so much attention?
Because the numbers, the watchdog findings, the academic research, and the Senate investigation all point in the same direction: denials are common, appeals are relatively rare, and a large share of appealed denials are reversed.
KFF found millions of denials and a very high reversal rate
KFF reported that Medicare Advantage insurers made 52.8 million prior authorization determinations in 2024, denied 4.1 million, and that only 11.5% of those appeals succeeded. But among those appealed denials, 80.7% were overturned in whole or in part. KFF also noted that across the years it examined, more than eight in ten appeals overturned the initial denial.
That does not prove every denial was wrongful. It shows that the initial denial is often not the final, reliable answer.
The HHS Office of Inspector General found denials that met Medicare rules.
In 2022, the U.S. Department of Health and Human Services Office of Inspector General (OIG) found that 13% of prior authorization denials in its reviewed sample were for service requests that met Medicare coverage rules. The OIG also found that 18.1% of payment denials in its reviewed sample were for claims that met Medicare coverage rules and Medicare Advantage billing rules. The agency said these denials likely delayed or prevented medically necessary care or delayed proper payment.
The OIG identified several causes, including the use of criteria not contained in Medicare coverage rules, requests for unnecessary documentation, and manual or system errors. That is an official federal watchdog report, not an anecdote.
Health Affairs found denial pressure beyond prior authorization alone
A 2025 study in Health Affairs examined claims data from multiple Medicare Advantage plans that covered about 30% of the Medicare Advantage market in 2019. The study found that 17% of initial claims were denied, and 57% of those denials were ultimately reversed, yet provider payouts still fell overall.
That matters because it suggests the pressure point is not limited to prior authorization alone. Friction can appear elsewhere in the claims process, too.
Senate investigators put post-acute care denials under a harsh spotlight.
In October 2024, the U.S. Senate Permanent Subcommittee on Investigations released a majority staff report stating that the nation’s three largest Medicare Advantage insurers used prior authorization to target stays in skilled nursing facilities, inpatient rehabilitation facilities, and long-term acute care hospitals. The Senate press release says the report detailed findings about barriers to care for seniors enrolled in Medicare Advantage. A separate Center for Medicare Advocacy summary says the report highlighted allegations that three major insurers intentionally used prior authorization to boost profits by denying post-acute care. Because that latter phrasing comes through an advocacy summary, not the press release itself, it should be understood as a reported characterization of the Senate report, not an adjudicated fact.
The report also drew heavily on earlier STAT reporting. In this context, STAT refers to STAT News, which on its official About page says its mission is to deliver “trusted, tough-minded journalism” on the business of making medicines, health tech, science, public health, hospitals, and insurance. STAT also reported that the Senate report extensively cited STAT’s earlier investigation into the use of algorithms and artificial intelligence within Medicare Advantage plans.
That does not mean every denial is automated or unlawful. It does mean the issue has drawn serious national investigative scrutiny and cannot honestly be dismissed as a string of isolated complaints.
Why this matters in Kentucky and Ohio
For patients in Kentucky and Ohio, the practical trap is confusion. A family often thinks it is dealing with an ordinary private-insurance dispute under state procedures. In reality, when the denial involves Medicare Advantage (Part C) or Part D, the appeal path is largely governed by the federal Medicare system. CMS maintains separate appeals and grievances frameworks for Parts C and D.
That means the most important deadlines and appeal instructions are usually in the notice itself and in the federal Medicare rules that underpin it. Medicare.gov says the plan must provide you with written instructions on how to appeal.
How do you know whether a denial is Part C or Part D?
If the denial concerns a medical service, facility stay, scan, surgery, home health service, rehabilitation, or another treatment-related issue, it is often a Part C issue. If the denial is about a prescription drug, formulary issue, quantity limit, step therapy requirement, or drug prior authorization, it is often a Part D problem. Medicare’s consumer guidance reflects that distinction between health-plan benefits and prescription-drug coverage.
That is not just vocabulary. It affects the form you use, the deadlines you follow, the evidence you gather, and the terminology the plan will use in its notices. CMS uses organization determination and reconsideration for Part C, and redetermination for the first Part D appeal.
What is the deadline to appeal a Medicare Advantage denial?
This is the article’s most important practical question.
CMS states that in November 2024, it updated the Parts C and D appeals guidance to reflect a regulatory change extending the time to submit an appeal from 60 calendar days to 65 calendar days from the date of the notice, effective January 1, 2025. CMS posted that update on both its Medicare Managed Care Appeals & Grievances and Medicare Prescription Drug Appeals & Grievances pages.
For Part C, CMS’s consumer-facing Medicare page says you, your representative, or your doctor or other provider must file an appeal within 65 days from the date on the initial denial notice sent by the plan.
For Part D, CMS’s 2024 update says the same timeframe change applies to Part D guidance. Because some older HHS pages still show the earlier 60-day language, the safest approach is to rely on the current CMS update and the current plan notice.
That change matters because many older articles and websites still refer to 60 days. The safer approach today is to follow current CMS guidance and treat the appeal deadline as 65 calendar days from the date on the notice, while acting much sooner in practice.
How fast does the plan have to decide the appeal?
Part C timelines
CMS says that once a Medicare Advantage plan receives a Part C reconsideration request, it must decide as quickly as the enrollee’s health requires, but no later than:
- 72 hours for expedited pre-service benefit or Part B drug requests,
- 30 calendar days for standard pre-service requests,
- 7 calendar days for standard Part B drug requests,
- and 60 calendar days for payment requests.
CMS also says that if the Part C reconsideration decision is unfavorable in whole or in part, the plan must forward the case for automatic review by the Part C Independent Review Entity (IRE).
Part D timelines
CMS says that once a Part D plan sponsor receives a redetermination request, it must make its decision and provide written notice as quickly as the enrollee’s health requires, but no later than 72 hours for expedited requests or 7 calendar days for standard requests. The governing regulation separately addresses favorable payment redeterminations within 14 calendar days.
In simple terms, if waiting could seriously jeopardize the patient’s health, the family should not focus solely on appealing. They should also ask whether the appeal should be expedited. Medicare.gov says a fast appeal is available when waiting for the standard decision could seriously jeopardize life, health, or the ability to regain maximum function.
How to read a Medicare Advantage denial letter in plain English
The letter may look dense, but there are really only a few questions that matter immediately.
- What exactly was denied?
Was it a rehabilitation stay, a skilled nursing stay, a surgery, a scan, home health, a prescription drug, a refill, a reimbursement request, or an exception request? That tells you whether you are likely dealing with Part C or Part D.
- Why did the plan say no?
Look for phrases such as “not medically necessary,” “not covered,” “not on formulary,” “prior authorization not obtained,” “step therapy required,” “quantity limit exceeded,” or “insufficient documentation.” A strong appeal does not just say the result is unfair. It answers the plan’s stated reason, point by point, with facts and records. Medicare.gov says you can ask your provider or supplier for information to strengthen your appeal.
- What is the deadline?
Under current CMS guidance, the first-level appeal deadline is generally 65 calendar days from the date on the notice. A family should not wait anywhere near that long. The safest course is to calendar the deadline immediately and begin building the record.
- Should the appeal be expedited?
If a delay could seriously harm the patient’s health, the family should ask whether the case qualifies for expedited review. CMS and Medicare.gov both provide accelerated timelines for qualifying appeals under Parts C and D.
- What evidence will answer the denial?
For Part C, that may include physician notes, hospital records, discharge summaries, therapy records, imaging, and a treating doctor’s letter explaining why the service is medically necessary.
For Part D, that may include the prescriber’s statement, treatment history, failed alternatives, side-effect history, urgency, and support for an exception if the drug is off formulary or otherwise restricted. Medicare.gov says a provider or supplier can often help supply the information needed to make the appeal stronger, and that a prescriber’s statement is required when asking for a Part D exception.
Why do so many people lose before the merits are ever tested?
Because exhaustion is part of the system.
A family dealing with illness is already short on time, sleep, and certainty. The denial letter arrives in bureaucratic language. The deadlines are easy to miss. The rules can feel built for professionals. KFF’s findings suggest that the biggest problem is not that every denial is correct. It is that most denials are never seriously challenged. Only 11.5% of denied prior authorization requests were appealed in 2024, even though 80.7% of appeals overturned denials in whole or in part.
That does not mean every appeal will win. It does mean the first denial should rarely be treated as the last word.
A simple example
Imagine an Ohio family whose mother suffers a stroke and needs more inpatient rehabilitation. The Medicare Advantage plan says additional days are not medically necessary. The family reads the letter and assumes the insurer has made a final clinical judgment.
But the appeal may tell a different story. Updated therapy notes, functional assessments, discharge records, physician support, and a focused response to the plan’s stated rationale can change the outcome. That is exactly why the KFF reversal figures matter. They show that many initial denials do not survive a serious challenge.
Or picture a Kentucky patient whose Part D plan denies a costly cancer or autoimmune drug. The denial may feel final, but it may only mean the patient must pursue a redetermination or request an exception supported by the prescribing doctor’s explanation of why the drug is necessary and why the listed alternatives are ineffective or unsafe. Medicare.gov’s formulary and drug-plan guidance, together with CMS’s Part D appeals rules, exist for that kind of dispute.
What Kentucky and Ohio families should do first
If a Medicare Advantage denial arrives, do these five things immediately.
Step 1: Figure out whether it is Part C or Part D.
That tells you which appeal track you are on.
Step 2: Protect the deadline.
Under current CMS guidance, the first-level appeal deadline is generally 65 calendar days from the notice date, but waiting is dangerous.
Step 3: Read the denial reason slowly.
The appeal should answer the plan’s reason with evidence, not just frustration.
Step 4: Ask whether the case should be expedited.
If delay threatens health, say so early and clearly.
Step 5: Do not assume the insurer’s initial answer is correct.
KFF, the OIG, Health Affairs, and the Senate investigation all support skepticism toward treating the first denial as final.
Frequently asked questions about Medicare Advantage denials
Is Medicare Advantage the same as Medicare Part C?
Yes. Medicare Advantage is the consumer-facing name, and Part C is the formal Medicare term for that coverage.
Is Medicare drug coverage the same as Part D?
Yes. Medicare prescription drug coverage is Part D.
How long do I have to appeal a denial?
Under current CMS guidance, the first-level appeal deadline is generally 65 calendar days from the date on the notice.
What if the patient cannot wait?
Ask immediately whether the case qualifies for an expedited appeal. CMS and Medicare.gov provide accelerated timelines for qualifying cases.
What if the drug is not on the plan’s formulary?
A drug that is not on the formulary may still be challenged through the plan’s exception and appeals process. Medicare.gov explains that each plan has its own formulary and drug rules, and that exception requests require a prescriber’s supporting statement.
The larger truth
A denial letter is not just paperwork. It can interrupt treatment, destabilize recovery, frighten a family, and create the false impression that the case is over.
But the best public evidence says something more complicated and more hopeful. Denials are common. Appeals are underused. And when people do appeal, a surprising number of denials are reversed. Some official federal reviews have found that denied requests met Medicare’s own rules. That is why silence after a denial can be as costly as the denial itself.
Need help understanding a Medicare Advantage denial in Kentucky or Ohio?
If you or a family member in Kentucky or Ohio received a denial involving Medicare Advantage (Part C) or Medicare prescription drug coverage (Part D), the safest next step is to slow down, read the notice carefully, identify the deadline, and understand which appeal path applies.
At Appealhealthcare.com, the goal is to help families understand what the denial means, what deadlines control, and what steps may strengthen the appeal record before time runs out.
Sources
KFF for the 2024 prior-authorization volume, denial rate, appeal rate, and overturn rate. (KFF)
CMS Medicare Managed Care Appeals & Grievances and CMS Medicare Prescription Drug Appeals & Grievances for the November 2024 update, extending the appeal-submission timeframe from 60 to 65 calendar days from the date of the notice. (CMS)
CMS Reconsideration by the Medicare Advantage (Part C) Health Plan for Part C reconsideration terminology and decision deadlines. (CMS)
CMS Redetermination by the Part D Plan Sponsor and 42 C.F.R. § 423.590 for Part D redetermination terminology and timing rules. (CMS)
Medicare.gov for the definitions of Medicare Advantage, Part C, Part D, formulary, plan drug rules, filing appeals, and expedited appeals. (Medicare)
The HHS Office of Inspector General found that 13% of the reviewed prior-authorization denials and 18.1% of the reviewed payment denials met Medicare rules. (HHS OIG)
Health Affairs’ 2025 study reported that 17% of initial claims were denied and that 57% were ultimately reversed. (STAT)
U.S. Senate Permanent Subcommittee on Investigations for the October 2024 report and press release on Medicare Advantage denials in post-acute care. (Blumenthal Senate)
STAT News for the definition of STAT and for reporting that the Senate report extensively cited STAT’s earlier investigation into algorithms and artificial intelligence within Medicare Advantage plans. (STAT)
DISCLAIMER: This blog post is intended for informational purposes only and is not legal advice. The information given should not be relied on as a substitute for obtaining legal advice from an attorney licensed to practice in your area. Reading this blog post or contacting our firm through this website does not create an attorney-client relationship. Every case is unique, and past results do not guarantee or predict future outcomes. Individual results may vary based on the specific facts, jurisdiction, parties involved, and other factors relevant to your situation.
ATTORNEY ADVERTISING: Frank M. Mungo, Attorney at Law. Office: 7310 Turfway Road, Suite 550, Florence, KY 41042 (859-372-6670). The choice of a lawyer is an important decision and should not be based only on advertisements.
